Evidera

Name

Evidera

Legal name

Evidera

Website

https://evidera.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Healthcare Real-World Evidence Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Engineering, Accounting, Research, Management (8700)

akta.pro primary industry

Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)

akta.pro secondary industries

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• Real-world evidence
• Health economics
• Patient-centered research
• Clinical registries
• Market access

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Research Services: Professional services revenue model providing real-world evidence solutions, observational studies, and consulting services to pharmaceutical and biotech companies throughout the product lifecycle from early development through post-market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Evidera is a healthcare research company that generates real-world evidence (RWE) and health economics insights for the life sciences industry. The firm designs and executes observational studies, patient-centered research, health economics analyses, market access solutions, and clinical registries that inform drug development, regulatory, and reimbursement decisions. Evidera operates as part of PPD, the clinical research business of Thermo Fisher Scientific, and serves pharmaceutical, biotechnology, government, HTA, and payor clients.

Product overview

Evidera, operating as PPD Evidera within Thermo Fisher Scientific's PPD clinical research business, offers a unified platform of real-world evidence solutions. The core PPD Evidera Real-World Evidence service integrates proprietary PPD CorEvitas Clinical Registries for regulatory-grade longitudinal data, supplemented by specialized sub-products including Observational Studies, Patient-Centered Research, Implementation Science, Real-World Data and Scientific Solutions, Pregnancy and Lactation Studies, and Health Economics & Market Access services. Together, these products enable evidence generation across the entire drug development lifecycle from early discovery through post-market surveillance, serving biopharmaceutical companies, government agencies, HTA bodies, and payors.

Differentiator

Problem solved

Functional benefit

Brands

• PPD Evidera Patient-Centered Research: Patient-centered research services focusing on engaging patients throughout the drug development process
• PPD Evidera Implementation Science
• PPD Evidera Health Economics
• PPD Evidera Market Access

Products and services

• PPD Evidera Real-World Evidence Real-world evidence generation services that use observational data to support clinical, regulatory, and commercial decision-making for life sciences clients.
• Observational Studies Design and execution of observational research studies to evaluate treatment outcomes, safety, and effectiveness in real-world clinical settings.
• Real-World Data and Scientific Solutions Analytical and scientific services built around real-world data assets to address evidence gaps for pharmaceutical and biotech sponsors.
• PPD Evidera Patient-Centered Research Patient-centered outcomes research that captures the patient experience, including patient-reported outcomes, quality of life, and preference studies.
• PPD Evidera Implementation Science Implementation science services that help sponsors translate clinical evidence into routine clinical practice and measurable health system outcomes.
• PPD CorEvitas Clinical Registries Prospective clinical registries that collect longitudinal real-world data on disease cohorts and treatment patterns to support evidence generation.
• PPD CorEvitas Precision Medicine Precision medicine registry and analytics services that link molecular and clinical data to support targeted therapy evidence generation.
• PPD Evidera Health Economics Health economics and outcomes research (HEOR) services, including economic modeling, burden-of-illness, and cost-effectiveness analyses for sponsors.
• PPD Evidera Market Access Market access services that develop evidence dossiers and value communications to support payer, HTA, and reimbursement decision-making.
• Pregnancy and Lactation Studies Dedicated real-world research programs that generate safety and outcome data on medication use during pregnancy and lactation.

Quantifiable outcome

• Real-world evidence complements clinical trial data by providing broader patient representation and real-world context for more accurate assessment of comparative effectiveness and safety outcomes
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Thermo Fisher ScientificcoreOthersEvidera is part of PPD, which is the clinical research business of Thermo Fisher Scientific. This ownership provides Evidera with substantial resources, global infrastructure, and integration with Thermo Fisher's broader laboratory and clinical research services.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Direct peers

• Parexel International: Global CRO with a dedicated real-world evidence and market access practice serving pharma and biotech across the product lifecycle. Competes with Evidera for observational studies, HEOR, and HTA submissions.
• IQVIA: Largest global CRO with an extensive real-world evidence, HEOR, and epidemiology practice built around linked patient data assets. Directly competes with Evidera for RWE, observational study, and market access engagements with biopharma.
• ICON plc: Top-five global CRO offering RWE, HEOR, outcomes research, and patient-centered solutions following its PRA Health Sciences and Symphony Health acquisitions. Competes head-to-head with Evidera on enterprise pharma RWE contracts.
• Syneos Health: Clinical and commercial services provider with real-world evidence, HEOR, and market access capabilities. Targets the same biopharma buyers as Evidera for late-phase and post-launch evidence generation.

Broad incumbents

• Oracle Health Sciences (formerly Cerner Enviza): Broader clinical research and real-world data platform within Oracle's health portfolio, providing EDC-adjacent RWE infrastructure. Overlaps with Evidera on real-world data analytics and study delivery at biopharma clients.
• Medidata Solutions (Dassault Systèmes): Clinical trial technology platform within Dassault Systèmes with real-world evidence and synthetic control arm capabilities. Competes partially with Evidera where sponsors prefer integrated software plus services for RWE generation.

Emerging players

• Veradigm (Allscripts): Real-world data and analytics provider built on ambulatory EHR data, supplying de-identified datasets and analytics for biopharma. Competes with Evidera on the upstream real-world data asset layer feeding RWE studies.
• Flatiron Health: Roche-owned real-world evidence provider focused on oncology EHR-derived datasets and point-of-care evidence generation. An emerging specialist competitor to Evidera's registry model in oncology and rare-disease RWE.
• TriNetX: Global health research network enabling protocol design, cohort feasibility, and real-world evidence on federated EHR data. Competes with Evidera on observational study design and rapid-cycle real-world analytics.
• Aetion: Real-world evidence analytics platform used for regulatory-grade outcomes and safety studies. An emerging specialist competitor to Evidera's RWD analytics and HEOR offerings, especially for payer and regulatory submissions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/evideraglobal
• YouTubeyoutube.com/PPDCRO
• Facebookfacebook.com/ppdcro
• LinkedInlinkedin.com/company/3231698

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evidera